LGALS9 and head and neck squamous cell carcinoma: ,43,44 In this context, the Gal-9-inhibiting antibody LYT-200 was recently granted fast-track development by the Food and Drug Administration in patients with recurrent or metastatic head and neck squamous cell carcinoma.